Dihydroergotamine: A review of formulation approaches for the acute treatment of migraine

CNS Drugs

Volumn 27, Issue 5, 2013, Pages 385-394

  Silberstein, Stephen D ^a   Kori, Shashidhar H ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MAP Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; BUTORPHANOL; CHLORPROMAZINE; DEXAMETHASONE; DIHYDROERGOTAMINE; DOPAMINE RECEPTOR; HYDROXYZINE; KETOROLAC; METOCLOPRAMIDE; NOSE SPRAY; PETHIDINE; PROCHLORPERAZINE; PROMETHAZINE; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SUMATRIPTAN; VALPROIC ACID;

CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); COUGHING; DISEASE SEVERITY; DIZZINESS; DRUG BINDING; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; EDEMA; HUMAN; MIGRAINE; NAUSEA; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; THROAT IRRITATION; TREATMENT DURATION; TREATMENT RESPONSE;

ANALGESICS, NON-NARCOTIC; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DIHYDROERGOTAMINE; HUMANS; MEDLINE; MIGRAINE DISORDERS;

EID: 84878562924     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0061-2     Document Type: Review

References (58)

1. Stovner LJ, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193-210.
2. Stewart WF, Wood GC, Manack A, et al. Employment and work impact of chronic migraine and episodic migraine. J Occup Environ Med. 2010;52(1):8-14.
3. Souza-e-Silva HR, Rocha-Filho PA. Headaches and academic performance in university students: a cross-sectional study. Headache. 2011;51(10):1493-502.
4. Merikangas KR, Cui L, Richardson AK, et al. Magnitude, impact, and stability of primary headache subtypes: 30 year prospective Swiss cohort study. BMJ. 2011;343:d5076.
5. Nq-Mak DS, Fitzgerald KA, Norquist JM, et al. Key concepts of migraine postdrome: a qualitative study to develop a post-migraine questionnaire. Headache. 2011;51(1):105-17.
6. Buse D, Manack A, Serrano D, et al. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52(1):3-17.
7. Dahlöf C, Maasen van den Brink A. Dihydroergotamine, ergotamine, methysergide and sumatriptan: basic science in relation to migraine treatment. Headache. 2012;52(4):707-14.
8. Horton BT. A new product in the treatment of migraine: a preliminary report. Proc Staff Meet Mayo Clin. 1945;20:241-8.
9. Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. Headache. 1997;37(Suppl. 1):S15-25.
10. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(6):754-62.
11. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine: revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968-81.
12. Géraud G, Lantéri-Minet M, Lucas C, et al. French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther. 2004;26(8):1305-18.
13. Baron EP, Tepper SJ. Revisiting the role of ergots in the treatment of migraine and headache. Headache. 2010;50(8):1353-61.
14. Morren JA, Galvez-Jimenez N. Where is dihydroergotamine mesylate in the changing landscape of migraine therapy? Expert Opin Pharmacother. 2010;11(18):3085-93.
15. Fisher M, Gosy EJ, Heary B, et al. Dihydroergotamine nasal spray for relief of refractory headache: a retrospective chart review. Curr Med Res Opin. 2007;23(4):751-5.
16. Dihydroergotamine Schürks M. Dihydroergotamine. Opin Drug Metab Toxicol. 2009;5(9):1141-8.
17. Rapoport A, Winner P. Nasal delivery of antimigraine drugs: clinical rationale and evidence base. Headache. 2006;46(Suppl. 4):S192-201.
18. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
19. Wyss PA, Rosenthaler J, Nüesch E, et al. Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects. Eur J Clin Pharmacol. 1991;41(6):597-602.
20. Little PJ, Jennings GJ, Skews H, et al. Bioavailability of dihydroergotamine in man. Br J Clin Pharmacol. 1982;13(6):785-90.
21. Shrewsbury SB, Cook RO, Taylor G, et al. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (Tempo™) inhaler. Headache. 2008;48(3):355-67.
22. van der Kuy PH, Lohman JJ, Hooymans PM, et al. Bioavailability of intranasal formulations of dihydroergotamine. Eur J Clin Pharmacol. 1999;55(9):677-80.
23. Humbert H, Cabiac MD, Dubray C, et al. Human pharmacokinetics of dihydroergotamine administered by nasal spray. Clin Pharmacol Ther. 1996;60(3):265-75.
24. Cook RO, Shrewsbury SB, Ramadan NM. Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: potential mechanism. Headache. 2009;49(10):1423-34.
25. Buzzi MG, Moskowitz MA. Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia. 1991;11(4):165-8.
26. Lesage AS, Wouters R, Van Gompel P, et al. Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol. 1998;123(8):1655-65.
27. 1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. Br J Pharmacol. 1999;128(6):1133-40.
28. Andersen AR, Tfelt-Hansen P, Lassen NA. The effect of ergotamine and dihydroergotamine on cerebral blood flow in man. Stroke. 1987;18(1):120-3.
29. Aellig WH, Rosenthaler J. Venoconstrictor effects of dihydroergotamine after intranasal and intramuscular administration. Eur J Clin Pharmacol. 1986;30(5):581-4.
30. Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache. 1986;26(4):168-71.
31. Belgrade MJ, Ling LJ, Schleevogt MB, et al. Comparison of single-dose meperidine, butorphanol, and dihydroergotamine in the treatment of vascular headache. Neurology. 1989;39(4):590-2.
32. Bell R, Montoya D, Shuaib A, et al. A comparative trial of three agents in the treatment of acute migraine headache. Ann Emerg Med. 1900;19(10):1079-82.
33. Klapper JA, Stanton JS. Ketorolac versus DHE and metoclopramide in the treatment of migraine headaches. Headache. 1991;31(8):523-4.
34. Klapper JA, Stanton JS. The emergency treatment of acute migraine headache: a comparison of intravenous dihydroergotamine, dexamethasone, and placebo. Cephalalgia. 1991;11(Suppl. 11):159-60.
35. Klapper JA, Stanton J. Current emergency treatment of severe migraine headaches. Headache. 1993;33(10):560-2.
36. Scherl ER, Wilson JF. Comparison of dihydroergotamine with metoclopramide versus meperidine with promethazine in the treatment of acute migraine. Headache. 1995;35(5):256-9.
37. Carleton SC, Shesser RF, Pietrzak MP, et al. Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache. Ann Emerg Med. 1998;32(2):129-38.
38. Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache. 2001;41(10):976-80.
39. Winner P, Ricalde O, Le Force B, et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol. 1996;53(2):180-4.
40. Hämäläinen ML, Hoppu K, Santavuori PR. Oral dihydroergotamine for therapy-resistant migraine attacks in children. Pediatr Neurol. 1997;16(2):114-7.
41. Tulunay FC, Karan O, Aydin N, et al. Dihydroergotamine nasal spray during migraine attacks: a double-blind crossover study with placebo. Cephalalgia. 1987;7(2):131-3.
42. Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology. 1994;44(3 Pt 1):447-53.
43. Dihydroergotamine Nasal Spray Multicenter Investigators. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Headache. 1995;35(4):177-84.
44. Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Arch Neurol. 1996;53(12):1285-91.
45. Touchon J, Bertin L, Pilgrim AJ, et al. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology. 1996;47(2):361-5.
46. Treves TA, Kuritzky A, Hering R, et al. Dihydroergotamine nasal spray in the treatment of acute migraine. Headache. 1998;38(8):614-7.
47. Aurora SK, Rozen TD, Kori SH, et al. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache. 2009;49(6):826-37.
48. Aurora SK, Silberstein SD, Kori SH, et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache. 2011;51(4):507-17.
49. Lipton RB, Bigal ME, Stewart WF. Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life. Neurology. 2005;65(12 Suppl. 4):S50-8.
50. Dowson AJ, Tepper SJ, Baos V, et al. Identifying patients who require a change in their current acute migraine treatment: the Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire. Curr Med Res Opin. 2004;20(7):1125-35.
51. Chopra R, Robert T, Watson DB. Non-pharmacological and pharmacological prevention of episodic migraine and chronic daily headache. W V Med J. 2012;108(3):88-91.
52. Friedman BW, Grosberg BM. Diagnosis and management of the primary headache disorders in the emergency department setting. Emerg Med Clin North Am. 2009;27(1):71-87.
53. Vinson DR, Hurtado TR, Vandenberg JT, et al. Variations among emergency departments in the treatment of benign headache. Ann Emerg Med. 2003;41(1):90-7.
54. Nijar SS, Pink L, Gordon AS. Examination of migraine management in emergency departments. Pain Res Manag. 2011;16(3):183-6.
55. Relja G, Granato A, Capozzoli F, et al. Nontraumatic headache in the emergency department: a survey in the province of Trieste. J Headache Pain. 2005;6(4):298-300.
56. Nagy AJ, Gandi S, Bhola R, et al. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology. 2011;77(20):1827-32.
57. Pringsheim T, Howse D. In-patient treatment of chronic daily headache using dihydroergotamine: a long-term follow-up study. Can J Neurol Sci. 1998;25(2):146-50.
58. Charles JA, von Dohln P. Outpatient home-based continuous intravenous dihydroergotamine therapy for intractable migraine. Headache. 2010;50(5):852-60.